The activation of caspase-3 and the presence of apoptotic bodies also exhibited clear differences in apoptosis (Figure 1B) versus the 177Lu-HuIgG treated tumor as depicted by immunohistochemistry (IHC) and haamatoxylin and eosin (H & E) staining, indicating effective, specific, targeted tumor killing by 177Lu-trastuzumab. The gene discussed is CASP3; the disease is neoplasm.